Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
The Use of Vendors in Medicare Part B Drug Payment
USC-Brookings Schaeffer Initiative experts provide an analysis of a voluntary vendor approach for Medicare to restrain drug spending for Part B drugs.
Posted in -
Medicare Beneficiaries, Especially Unsubsidized Minorities, Struggle to Pay for Prescription Drugs: Results from the Medicare Current Beneficiary Survey
This paper examines racial/ethnic disparity in prescription drug cost-coping behaviors in a nationally representative sample of Medicare beneficiaries.
Posted in -
CMS’s International Pricing Model for Medicare Part B Drugs: Implementation Issues
To lower the Part B portion of drug spending, the Trump Administration has proposed a demonstration project tying Medicare reimbursement for outpatient, physician-administered drugs to international prices. Paul Ginsburg and Steven Lieberman explore the potential consequences of such a rule.
-
Louisiana’s Prescription Drug Experiment: A Model for the Nation?
On July 22, the USC-Brookings Schaeffer Initiative for Health Policy will hosted a conference on Louisiana's subscription model to expand access to Hepatitis C treatment for the state's incarcerated and Medicaid patients with the infection.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
Do Cancer Treatments Have Option Value? Real‐ World Evidence From Metastatic Melanoma
The study findings in metastatic melanoma provide the first empirical evidence of the impact of option value in cancer treatment decision making.
Categorized in -
Here’s How We Can Control Drug Costs While Spurring Innovation
It’s time to bring back the U.S. Federal Office of Technology Assessment with a sharper focus on medical innovation, writes USC Schaeffer Center Director Dana Goldman in The Hill.
Categorized in -
Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling
Peer-reviewed journals could make a key contribution to improving scientific rigor and real-world healthcare decision-maker acceptability by requiring that VHDM models, source code, and data used in published articles be made freely available to interested readers.
Categorized in -
State and Federal Policy Solutions to Rising Prescription Drug Prices in the U.S.
States are addressing drug pricing issues through one of two domains. First, states are targeting drug pricing directly for both branded and generic products. Second, states are exploring topics in drug price transparency. Padula outlines state and federal policy options targeted prescription drugs that are currently being pursued.
Categorized in -
Economic Dimensions of Personalized and Precision Medicine
The book explores recent empirical applications of personalized and precision medicine, as well as the intersection of the scientific, clinical, and economic factors affecting the development of PPM.
-
Impact of Oncology Drug Shortages on Chemotherapy Treatment
Jacobson and Alpert studied more than 2.4 million monthly claims for chemotherapy treatment and found little impact on outpatient chemotherapy treatment for the majority of oncology drugs identified as experiencing shortages between 2004 and 2011.
Categorized in